Contact

Simplifying manufacturing of alphavirus self-amplifying RNA replicons

How CleanCap® co-transcriptional capping strategy can be advantageous

Self-amplifying RNAs (saRNAs), also known as self-replicating (srRNAs), are emerging as a powerful tool in vaccine development. Unlike traditional mRNA vaccines, saRNAs have the ability to replicate inside cells, potentially leading to stronger and longer-lasting immune responses even at lower doses.

However, this advantage may come with a manufacturing hurdle. saRNAs are typically longer than standard mRNAs, and their natural starting sequence differs from a typical start site of T7 RNA polymerase for in vitro transcription. These factors can pose challenges in in vitro RNA capping, which is essential for efficient RNA production and optimal functionality.

This technical note covers the following aspects:

  • Vaccine development using alphavirus-adapted self-amplifying RNAs
  • Basics of self-amplifying RNA replicons
  • Challenges associated with capping alphavirus RNA
  • Common capping methods for alphavirus RNA replicons and their usage considerations
sarna-capping-technote_small_jpg

Read the technical note

Please complete the form to download the tech note and learn about the considerations for using common approaches to cap saRNAs.

Cleancap Au Tech Note

Cleancap Au Tech Note
Privacy policy
TriLink BioTechnologies does not sell or distribute your information to 3rd parties. For more information, please refer to our Privacy Policy.